Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Ipamorelin: does it work, is it legal, and what does it cost?

Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about Ipamorelin
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: Nomination withdrawn

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [6] [15] See legal status

What does it cost?Not available through licensed channels. Insurance does not cover it. See cost by channel
Side effects?No safety signal versus placebo in the 7 day intravenous ileus trial (adverse events 87.5% versus 94.8%, mostly surgical). Injection site reactions, headache, flushing, and lightheadedness reported anecdotally. Increased appetite (ghrelin receptor effect) reported anecdotally. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is Ipamorelin?

Ipamorelin is a five amino acid ghrelin receptor agonist (it activates the receptor for the hunger hormone ghrelin) developed in the 1990s as a growth hormone secretagogue, a drug that makes the pituitary release growth hormone, that unlike GHRP-2 and GHRP-6 does not raise cortisol or prolactin in animals. The only randomized human trial tested it for postoperative ileus (the gut stalling after bowel surgery) and found no significant benefit. One small pharmacology study showed a single IV (into a vein) infusion releases GH in healthy men, but there is no human trial of ipamorelin for GH deficiency, body composition, recovery, or sleep, which are the uses it is sold for. FDA placed it on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) in September 2023, the nominators withdrew its 503A nomination in 2024, and it is now listed as a withdrawn 503A nomination with no federal basis for compounding (custom-making by a pharmacy); ipamorelin acetate remains in 503B Category 2.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue; selective agonist at the ghrelin receptor (GHS-R1a). It is also known as Ipamorelin acetate, NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2, CJC-1295/ipamorelin blend.

How does it work?

Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor) on pituitary somatotrophs and hypothalamic neurons, triggering GH release through a pathway separate from GHRH. In rats and pigs its potency and efficacy for GH release matched GHRP-6, but it did not raise ACTH, cortisol, prolactin, LH, FSH, or TSH even at doses 200 fold above the GH ED50. Ghrelin receptor activation also stimulates gastric motility, which is why it was later tested for postoperative ileus.

Key facts
ClusterMetabolic and growth hormone axis
RoutesSubcutaneous injection (as sold, no human pharmacokinetic publication); Intravenous infusion (human ileus trial); Intranasal (anti-doping metabolite study only)
Conditions studiedGrowth hormone deficiency and GH secretagogue use
Recordv5, reviewed, verified Sep 30, 2026

Ipamorelin benefits: what the evidence shows

Evidence: Human RCT evidenceGrade assigned per the methodology.

One multicenter, randomized, double blind, placebo controlled phase 2 trial (117 adults enrolled, 114 analyzed) tested intravenous ipamorelin for postoperative ileus, the gut stalling after bowel surgery. Time to the first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p = 0.15), so the trial found no benefit, though the drug was well tolerated for up to 7 days. A separate pharmacology study in 40 healthy men found that a single intravenous infusion releases growth hormone. No randomized trial has tested ipamorelin for muscle, fat loss, recovery, anti-aging, or sleep, the uses it is sold for.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials1117
Human observational studies140
Animal studies3n/a
All indexed studies5157

Human evidence

Beck 2014 (Ipamorelin 201 Study Group): 117 adults enrolled after small or large bowel resection, 114 analyzed, randomized to 0.03 mg/kg intravenous ipamorelin or placebo twice daily on postoperative days 1 to 7. Median time to first tolerated solid meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p = 0.15); secondary endpoints also did not differ. Treatment emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of placebo, with no safety signal. A 1999 dose escalation study in 40 healthy men found that a single 15 minute IV infusion released GH at all five infusion rates, with a terminal half-life of about 2 hours; no published trial measures GH or IGF-1 responses to the subcutaneous doses used outside research. No indexed human trial for GH deficiency, body composition, or sleep identified.

Animal evidence

Raun 1998: in rat pituitary cells ipamorelin released GH with potency similar to GHRP-6; in anesthetized rats and conscious pigs it released GH with comparable efficacy while, unlike GHRP-2 and GHRP-6, not raising ACTH or cortisol. Johansen 1999: ipamorelin increased longitudinal bone growth in rats. Venkova 2009 and Greenwood-Van Meerveld 2012: ipamorelin accelerated gastric emptying and reversed delayed transit in rodent models of postoperative ileus, which motivated the human trial.

Key studies

Indexed studies of Ipamorelin
StudyDesign and populationOutcomeGrade
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients2014 PMID 25331030Multicenter, randomized, double blind, placebo controlled phase 2 trial, intravenous dosing up to 7 daysn = 117 Adults after open or laparoscopic small or large bowel resectionMedian time to first tolerated meal 25.3 hours versus 32.6 hours with placebo (p = 0.15); no significant difference on any efficacy endpoint; well toleratedEvidence: Human RCT evidence
Ipamorelin, the first selective growth hormone secretagogue1998 PMID 9849822In vitro rat pituitary cell assays plus in vivo studies in anesthetized rats and conscious pigsRat pituitary cells, rats, and pigsGH release comparable to GHRP-6 (pig ED50 2.3 nmol/kg) with no increase in ACTH, cortisol, prolactin, LH, FSH, or TSHEvidence: Animal-only evidence
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats1999 PMID 10373343Controlled animal studyRatsIncreased longitudinal bone growth and IGF-1 related markers with repeated dosingEvidence: Animal-only evidence
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus2009 PMID 19289567Controlled animal studyRats with surgically induced postoperative ileusIpamorelin accelerated gastric emptying and intestinal transit, motivating the later human trialEvidence: Animal-only evidence
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers1999 PMID 10496658Dose escalation pharmacokinetic and pharmacodynamic study, five IV infusion ratesn = 40 Healthy men (8 per dose level)A single 15 minute IV infusion released GH at all dose levels, with a single GH peak at about 0.67 hours and a terminal half-life of about 2 hours; no clinical or body composition outcomeEvidence: Human observational evidence

Conditions studied

Conditions with evidence for Ipamorelin
ConditionGradeNote
Growth hormone deficiency and GH secretagogue useEvidence: Human observational evidenceA pharmacology study in 40 healthy men found a single intravenous infusion releases growth hormone; its one randomized, placebo-controlled trial tested intravenous ipamorelin after bowel surgery (117 patients) and found no benefit; no randomized trial for growth hormone deficiency or the uses it is sold for; development stopped; listed by FDA as a withdrawn 503A nomination since April 2026.

Is Ipamorelin legal in the United States?

Regulatory: Nomination withdrawnWADA: WADA prohibited

FDA and compounding status

Not FDA approved for any use. Ipamorelin was nominated for the 503A bulks list and placed in Category 2. FDA cited immunogenicity risk from aggregation or peptide related impurities, unnatural amino acids that complicate characterization, and a published report of serious adverse events, including a death, when it was given intravenously. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted against adding ipamorelin free base or ipamorelin acetate to the 503A bulks list. FDA now lists ipamorelin acetate among 503A nominations withdrawn by the nominators, which puts it in no 503A category and outside FDA's interim policy. Ipamorelin acetate also remains in 503B Category 2, added September 29, 2023. It is not on the 503A bulks list, so as of the last verification date neither 503A pharmacies nor 503B outsourcing facilities have a federal basis to compound it.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

  2. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

  3. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

  4. WADA

    WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

    The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

  5. FDA

    FDA places GHRP-2, GHRP-6, and ipamorelin in 503B Category 2

    On September 29, 2023 FDA added growth hormone releasing peptide-2 (GHRP-2, for injectable and nasal routes), GHRP-6, and ipamorelin acetate to Category 2 under the 503B interim policy, citing immunogenicity risk from aggregation and peptide related impurities and, for GHRP-2, reports of serious adverse events. Outsourcing facilities may not compound a substance while it is in 503B Category 2. All three remain listed on the FDA page current as of April 22, 2026.

  6. FDA

    FDA places a batch of nominated peptides in 503A Category 2

    In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.

Full tracker for Ipamorelin or the category-wide tracker.

Email me when Ipamorelin's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of Ipamorelin used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Not established in human literature for GH related use. The only human RCT used 0.03 mg/kg intravenously twice daily for up to 7 days for postoperative ileus. Animal GH release studies used nanomole per kilogram intravenous doses (rat ED50 about 80 nmol/kg; pig ED50 about 2.3 nmol/kg). No human dose finding study for subcutaneous ipamorelin has been published.

Routes reported

Routes of administration reported for Ipamorelin
#Route
1Subcutaneous injection (as sold, no human pharmacokinetic publication)
2Intravenous infusion (human ileus trial)
3Intranasal (anti-doping metabolite study only)

Ipamorelin side effects

Side effects

Side effects reported for Ipamorelin
#Reported side effect
1No safety signal versus placebo in the 7 day intravenous ileus trial (adverse events 87.5% versus 94.8%, mostly surgical)
2Injection site reactions, headache, flushing, and lightheadedness reported anecdotally
3Increased appetite (ghrelin receptor effect) reported anecdotally
4FDA cited immunogenicity risk from aggregation and impurities and limited safety data by the routes used in compounding when it placed ipamorelin in Category 2
5Theoretical GH and IGF-1 related effects (fluid retention, insulin resistance, growth of existing tumors) untested in humans at marketed doses

Interactions

Interactions reported for Ipamorelin
#Interaction
1No formal human interaction studies exist
2Glucocorticoids and somatostatin analogs blunt GH release from any secretagogue
3Diabetes medications: GH raises glucose, so a theoretical effect on insulin requirements exists
4Often sold blended with CJC-1295; the combination has never been tested in humans

Contraindications

Contraindications for Ipamorelin
#Contraindication
1Active malignancy (GH and IGF-1 are growth promoting; no human safety data)
2Pregnancy and breastfeeding (no data)
3Competitive athletes subject to WADA testing (named in section S2)

How do people access Ipamorelin legally?

Typical cost: Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    Not legally available through a licensed pharmacy (no active 503A nomination, not on the bulks list, not an approved drug).

  • Not available

    Clinics that still advertise compounded ipamorelin are dispensing outside FDA's stated categories; ask what the legal basis is.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare Ipamorelin

What's actually offered, and what that means for you

Many clinics offer ipamorelin anyway. FDA has also found compounding pharmacies and an online seller offering it. [11] [12] [13] [14]

Being offered does not change the legal status of ipamorelin. Ipamorelin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [6] [15]

What FDA found

  • August 2026: FDA found an online seller offering a tesamorelin and ipamorelin mix, on a site that also marketed bacteriostatic water and a peptide calculator, and called it an unapproved new drug despite research-use-only labels. [13]
  • October 2024: FDA's review said ipamorelin is offered extensively in US med spas, wellness clinics, and concierge services, and found compounding pharmacy websites offering it alone or with CJC-1295 or sermorelin. [14]
  • January 2022: A compounding pharmacy had made a sermorelin and ipamorelin injection and recalled it in July 2021 because sterility could not be assured. [12]
  • April 2020: FDA named ipamorelin among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [11]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [15] [16] [17] [18] [19] [20]

What that means for you

  • A pharmacy that compounds ipamorelin is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [16] [17]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [20]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [21]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [22] [23]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [15]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, ipamorelin is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [8]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound ipamorelin, with or without a prescription. [6]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [24] [25] [26]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [26] [27] [28]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [20] [29] [30] [31] [32] [33]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [20]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [24]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [28]
  • Pharmacy: Is this made for me on a prescription written in my name? [27]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [26] [28]
  • Prescriber: What is the legal basis for a pharmacy to compound ipamorelin? Is it FDA approved or on the 503A bulks list? [6] [20]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [28]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [21]

Blends that contain Ipamorelin

Ipamorelin is sold in premixed blends under the names below. No blend has been tested as a combination, and a mix is only as lawful as its least lawful ingredient.

All peptide blends

Frequently asked questions

What is ipamorelin?

Ipamorelin is a synthetic five amino acid peptide that activates the ghrelin receptor (the receptor for the hunger hormone ghrelin) and makes the pituitary gland release growth hormone. Developed in the 1990s, it was described as the first selective growth hormone secretagogue (growth hormone releaser) because in animals it released growth hormone without raising cortisol or prolactin. In people it was tested only for bowel recovery after surgery, where it did not help, and it has never been approved. [1] [2]

Is ipamorelin legal in the United States?

It is not an FDA approved drug and has no federal basis to be compounded from bulk. FDA put ipamorelin on the 503A Category 2 list (substances with significant safety risks) in September 2023, the companies that nominated it withdrew those 503A nominations in 2024, and in April 2026 FDA moved it to the list of withdrawn nominations. That is not a listing on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it, and ipamorelin acetate remains in 503B Category 2. Possession is not a crime, but selling it for human use is unlawful: research chemical versions are unapproved drugs. [6] [7] [10]

Ipamorelin benefits: what does the evidence show?

No trial has tested the benefits it is sold for. In rats and pigs ipamorelin releases GH about as well as GHRP-6, and in rats it increased bone growth. In humans the only randomized, placebo controlled trial tested it for bowel recovery after surgery, not body composition, and found no benefit. One small study found a single IV infusion releases GH in healthy men, but no published trial measures GH, IGF-1, muscle, or fat changes from the subcutaneous product sold today. PeptideAgent grades ipamorelin as having human randomized trial evidence because that trial exists; the grade describes how the evidence was gathered, not whether the peptide works. [1] [2] [3] [9]

What are the side effects of ipamorelin?

In the only human RCT, 7 days of intravenous ipamorelin after bowel surgery produced no more adverse events than placebo (87.5% versus 94.8%, mostly surgical). Anecdotal reports with subcutaneous use mention injection site reactions, headache, flushing, lightheadedness, and increased appetite. FDA's Category 2 evaluation flagged immunogenicity risk from peptide aggregation and impurities. Long term effects of raising GH this way in adults are unstudied. [1] [6]

How much does ipamorelin cost?

There is no licensed channel, so there is no legitimate price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [6] [10]

Is ipamorelin banned by WADA?

Yes. Ipamorelin is named in section S2 of the WADA Prohibited List under growth hormone secretagogues (with GHRP-2, GHRP-6, hexarelin, and ibutamoren) and is prohibited at all times. Anti-doping laboratories have published methods to detect it and its metabolites in urine. [5] [8]

Ipamorelin vs CJC-1295: what is the difference and why are they combined?

They act on different receptors. Ipamorelin is a ghrelin receptor agonist; CJC-1295 is a long acting GHRH analog. In theory activating both pathways releases more GH than either alone, which is why clinics sold them blended, but that combination has never been tested in a human trial. CJC-1295 has small human RCTs showing sustained GH and IGF-1 increases; ipamorelin has only one small IV pharmacology study of GH release in healthy men. Both were placed in Category 2 in 2023 and both are now withdrawn 503A nominations, so neither can be lawfully compounded. [2] [6] [9]

Why is ipamorelin called the cleanest GH secretagogue?

Because of the 1998 animal pharmacology. In pigs, GHRP-2 and GHRP-6 raised ACTH and cortisol along with GH, while ipamorelin released GH without raising ACTH, cortisol, prolactin, LH, FSH, or TSH, even at very high doses. That selectivity is real in animals, but it has not been confirmed in a human trial at the doses people use. [2]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

More on the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
  2. [2]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
  3. [3]Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res 1999PubMed 10373343, 1999
  4. [4]Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009PubMed 19289567, 2009
  5. [5]Semenistaya E et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal 2015PubMed 25869809, 2015
  6. [6]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA, 2026
  7. [7]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  8. [8]WADA Prohibited List, section S2 (growth hormone secretagogues, including ipamorelin)WADA, 2026
  9. [9]Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999PubMed 10496658, 1999
  10. [10]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). Ipamorelin: evidence, legality, and access. https://peptideagent.ai/peptides/ipamorelin
HTML link
<a href="https://peptideagent.ai/peptides/ipamorelin">Ipamorelin: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.